Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

NCT07198074 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

255

Enrollment

NIH

Sponsor class

Conditions

Advanced Endometrial Carcinoma
Recurrent Endometrial Carcinoma

Interventions

BIOLOGICAL: Bevacizumab
PROCEDURE: Biospecimen Collection
DRUG: Carboplatin
PROCEDURE: Computed Tomography
PROCEDURE: Magnetic Resonance Imaging
DRUG: Paclitaxel
BIOLOGICAL: Pembrolizumab

Sponsor

National Cancer Institute (NCI)